Jul 2026· Journal of Alzheimer's Disease· Vol 113, pp. 650 - 660· 0 citations· 29 references
Medicine
TL;DR
Deep learning–based amyloid PET segmentation enables accurate MRI-free quantification of gray and white matter SUVRs and simplifies clinical workflow while maintaining diagnostic performance comparable to MRI-based methods for AD diagnosis.
Abstract
Background Accurate quantification of standardized uptake value ratio (SUVR) in amyloid PET is essential for Alzheimer's disease (AD) diagnosis but typically requires MRI-based segmentation due to subtle uptake differences between gray and white matter. Objective This study aimed to develop and validate a 3-dimensional deep learning model capable of segmenting these tissues directly from PET images to enable MRI-free SUVR quantification for AD diagnosis. Methods This retrospective study included 385 participants who underwent brain amyloid PET and MRI. After excluding 12 data-corrupted cases, 373 subjects were divided into training (n = 318) and test (n = 55) sets. External validation used 625 PET/CT scans from the Alzheimer's Disease Neuroimaging Initiative. Model performance was assessed using Dice coefficients and intersection over union. PET-based SUVRs derived from model-generated masks were compared with MRI-based SUVRs using Spearman correlation, and their diagnostic utility was evaluated by group differences and receiver operating characteristic analysis. Results The model achieved high Dice coefficients for grey matter (GM; 0.785 internal, 0.743 external) and white matter (WM; 0.838 internal, 0.803 external). PET/CT-based SUVR values strongly correlated with MRI references (Spearman's ρ ≥ 0.98, p < 0.001). PET/CT-derived SUVRGM and SUVRGM/WM predicted amyloid status (AUC 0.86 and 0.85, respectively) and cognitive impairment (AUC 0.78). Conclusions Deep learning–based amyloid PET segmentation enables accurate MRI-free quantification of gray and white matter SUVRs. This approach simplifies clinical workflow while maintaining diagnostic performance comparable to MRI-based methods for AD diagnosis.
High-resolution dhPET revealed significantly higher SUVRs in Aβ⁺ compared with Aβ⁻ subjects in supratentorial structures, including cerebral white matter, and in cerebellar gray matter.
Yasuyuki Kojita, Kazunari Ishii, Takahiro Yamada et al.· Annals of Nuclear Medicine· 0 citations
Hypometabolism is a sensitive and early marker of AD-related neurodegeneration, preceding MRI-detectable GM atrophy and more closely reflecting underlying tau pathology across disease stages.
Orfeas Vourkas, Linda Zhang, Andrés Jiménez-Pérez et al.· European Journal of Nuclear...· 0 citations
The proposed framework enables non-invasive Aβ mapping using a clinically feasible MRI protocol and may support repeated assessment for monitoring during anti-amyloid treatment.
Shohei Fujita, Y. Fushimi, Y. Otsuka et al.· Magnetic Resonance in Medica...· 0 citations
Alzheimer’s disease (AD) is the leading cause of dementia and disproportionately affects women, who experience a higher lifetime risk and more rapid structural brain changes than men. Reliable imaging biomarkers are essential for detecting these changes, although their estimation may be influenced by voxel geometry, im...
Abstract INTRODUCTION Tau positron emission tomography (PET) probes Alzheimer's disease (AD) severity via regional tau spread but is not widely available. We tested whether multiregion structural magnetic resonance imaging (MRI) could approximate individual tau burden. METHODS We studied 378 Alzheimer's Disease Neuroim...
Martina Pulze, S. Garbarino, L. Lorenzini et al.· Alzheimer's & Dementia· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.